Phathom Pharmaceuticals (PHAT) News
Market Cap: $358.63M
Avg Volume: 1.20M
Industry: Biotechnology
Sector: Healthcare
Phathom Pharmaceuticals to Present at the 24th Annual Needham Virtual Healthcare Conference
FLORHAM PARK, N.J., April 03, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, announced today that members of the management team will participate in a fireside chat at the 24th Annual Needham Virtual Healthcare Conference on Tuesday, April 8th, 2025, at 10:15 am ET.
globenewswire.com
Read More
Phathom Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
FLORHAM PARK, N.J., April 01, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, today announced that, in connection with the appointment of Steven Basta as President and Chief Executive Officer, the Company's Board of Directors has approved the grant of inducement awards.
globenewswire.com
Read More
Phathom Pharmaceuticals Announces Leadership Succession
FLORHAM PARK, N.J., April 01, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, today announced that Steven Basta has been appointed President and Chief Executive Officer and a member of the Board of Directors, effective immediately. Mr. Basta succeeds Terrie Curran, who is stepping down as President and CEO and as a member of the Board of Directors for personal reasons.
globenewswire.com
Read More
Actor and Comedian Kenan Thompson Teams Up with Phathom Pharmaceuticals to Raise Awareness About GERD and VOQUEZNA® (vonoprazan)
For the first time, Thompson shares his journey living with gastroesophageal reflux disease (GERD) and experience using VOQUEZNA, as part of the new GERD IS NO JOKE campaign VOQUEZNA is a potassium competitive acid blocker (PCAB), the first and only FDA-approved treatment of its kind for both types of GERD 1 A Media Snippet accompanying this announcement is available by clicking on this link. FLORHAM PARK, N.J.
globenewswire.com
Read More
Phathom Pharmaceuticals, Inc. (PHAT) Q4 2024 Earnings Call Transcript
Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT ) Q4 2024 Earnings Conference Call March 6, 2025 8:30 AM ET Company Participants Eric Sciorilli - Head, Investor Relations Terrie Curran - President & Chief Executive Officer Martin Gilligan - Chief Commercial Officer Molly Henderson - Chief Financial Officer Conference Call Participants Yatin Suneja - Guggenheim Joseph Stringer - Needham Annabel Samimy - Stifel Kristen Kluska - Cantor Fitzgerald Paul Choi - Goldman Sachs Matthew Caufield - H.C. Wainwright Operator Hello, and welcome to the Phathom Pharmaceuticals Fourth Quarter and Full Year 2024 Earnings Results Call.
seekingalpha.com
Read More
Phathom Pharmaceuticals, Inc. (PHAT) Reports Q4 Loss, Tops Revenue Estimates
Phathom Pharmaceuticals, Inc. (PHAT) came out with a quarterly loss of $0.79 per share versus the Zacks Consensus Estimate of a loss of $0.98. This compares to loss of $0.80 per share a year ago.
zacks.com
Read More
Phathom Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
FLORHAM PARK, N.J., March 06, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, today reported financial results for the fourth quarter and full year ended December 31, 2024, and provided recent business updates.
globenewswire.com
Read More
Phathom Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update on Thursday, March 6, 2025
FLORHAM PARK, N.J., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, today announced that it will host a live webcast at 8:30 am ET on Thursday, March 6, 2025, to report its fourth quarter and full year 2024 financial results and provide a business update.
globenewswire.com
Read More
Phathom Pharmaceuticals to Present at the Guggenheim Securities SMID Cap Biotech Conference
FLORHAM PARK, N.J., Jan. 29, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, announced today that members of the management team will participate in a fireside chat at the Guggenheim Securities SMID Cap Biotech Conference on Thursday, February 6, 2025, at 10:00 am ET.
globenewswire.com
Read More
Phathom Pharmaceuticals Submits Citizen Petition to FDA Seeking Correction of Orange Book Listings for VOQUEZNA® (vonoprazan) Tablets
FLORHAM PARK, N.J., Dec. 11, 2024 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, announced today it has submitted a Citizen Petition (CP) with the U.S. Food and Drug Administration (FDA). The petition formally requests correction of the Orange Book listings for VOQUEZNA (vonoprazan) 10 mg and 20 mg tablets to accurately reflect the full 10-year NCE exclusivity period until May 3, 2032.
globenewswire.com
Read More
Down -54.05% in 4 Weeks, Here's Why Phathom Pharmaceuticals (PHAT) Looks Ripe for a Turnaround
Phathom Pharmaceuticals (PHAT) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
zacks.com
Read More
Phathom Pharmaceuticals (PHAT) Upgraded to Buy: Here's What You Should Know
Phathom Pharmaceuticals (PHAT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
zacks.com
Read More
Phathom Pharmaceuticals, Inc. (PHAT) Q3 2024 Earnings Call Transcript
Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT ) Q3 2024 Earnings Conference Call November 7, 2024 8:30 AM ET Company Participants Eric Sciorilli - Head of Investor Relations Terrie Curran - President & Chief Executive Officer Martin Gilligan - Chief Commercial Officer Molly Henderson - Chief Financial & Business Officer Azmi Nabulsi - Chief Operating Officer Conference Call Participants Annabel Samimy - Stifel Paul Choi - Goldman Sachs Joseph Stringer - Needham & Company Yatin Suneja - Guggenheim Chase Knickerbocker - Craig-Hallum Matthew Caufield - H.C. Wainwright Operator Hello, and welcome to the Phathom Pharmaceuticals Third Quarter 2024 Earnings Results Call.
seekingalpha.com
Read More
Phathom Pharmaceuticals, Inc. (PHAT) Reports Q3 Loss, Tops Revenue Estimates
Phathom Pharmaceuticals, Inc. (PHAT) came out with a quarterly loss of $1.32 per share versus the Zacks Consensus Estimate of a loss of $1.57. This compares to loss of $0.76 per share a year ago.
zacks.com
Read More
Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences
FLORHAM PARK, N.J., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, announced today that members of its management team are scheduled to participate in the following investor conferences in November and December:
globenewswire.com
Read More
Phathom Pharmaceuticals to Report Third Quarter 2024 Financial Results and Provide Business Update on Thursday, November 7, 2024
FLORHAM PARK, N.J., Oct. 28, 2024 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, today announced that it will host a live webcast at 8:30 am ET on Thursday, November 7, 2024, to report its third quarter 2024 financial results and provide a business update.
globenewswire.com
Read More
Phathom Pharmaceuticals to Present VOQUEZNA® Data at the American College of Gastroenterology (ACG) 2024 Annual Meeting
FLORHAM PARK, N.J., Oct. 27, 2024 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, today announced that the company will present data from multiple investigational studies for its first-in-class treatment VOQUEZNA® (vonoprazan) tablets at the American College of Gastroenterology (ACG) 2024 Annual Scientific Meeting, being held October 25-30 in Philadelphia, PA. VOQUEZNA is approved for the relief of heartburn associated with Non-Erosive Gastroesophageal Reflux Disease (Non-Erosive GERD), for the treatment of all severities of Erosive Esophagitis, commonly referred to as Erosive GERD, and relief of related heartburn, and in combination with antibiotics for the eradication of Helicobacter pylori (H. pylori) infection.1 VOQUEZNA is the first and only U.S. Food and Drug Administration (FDA)-approved potassium-competitive acid blocker (PCAB).2
globenewswire.com
Read More
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT)
NEW YORK , Sept. 25, 2024 /PRNewswire/ -- Levi & Korsinsky announces that it has commenced an investigation of Phantom Pharmaceuticals, Inc. (NASDAQ: PHAT) concerning possible breaches of fiduciary duty.
prnewswire.com
Read More
Phathom Pharmaceuticals Announces Pricing of $130 Million Offering of Common Stock and Pre-Funded Warrants
FLORHAM PARK, N.J., Aug. 19, 2024 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, announced today the pricing of its underwritten offering of 8,695,652 shares of its common stock and pre-funded warrants to purchase 2,608,922 shares of common stock. The shares of common stock are being sold at a price of $11.50 per share and the pre-funded warrants are being sold at a price of $11.499 per pre-funded warrant, which represents the per share price for the common stock less the $0.001 per share exercise price for each such pre-funded warrant. The gross proceeds to Phathom from the offering, before deducting the underwriting discounts and commissions and other offering expenses, are expected to be approximately $130 million. The offering is expected to close on or about August 20, 2024, subject to satisfaction of customary closing conditions.
globenewswire.com
Read More
Phathom Pharmaceuticals, Inc. (PHAT) Q2 2024 Earnings Call Transcript
Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT ) Q2 2024 Results Conference Call August 8, 2024 8:30 AM ET Company Participants Eric Sciorilli - Head of Investor Relations Terrie Curran - President and CEO Martin Gilligan - Chief Commercial Officer Molly Henderson - Chief Financial Officer Azmi Nabulsi - Chief Operating Officer Conference Call Participants Annabel Samimy - Stifel Joseph Stringer - Needham & Company Yatin Suneja - Guggenheim Paul Choi - Goldman Sachs Chase Knickerbocker - Craig-Hallum Matthew Caufield - H.C. Wainwright Operator Hello, and welcome to Phathom Pharmaceuticals Second Quarter 2024 Earnings Results Call.
seekingalpha.com
Read More
Phathom Pharmaceuticals, Inc. (PHAT) Reports Q2 Loss, Tops Revenue Estimates
Phathom Pharmaceuticals, Inc. (PHAT) came out with a quarterly loss of $1.25 per share versus the Zacks Consensus Estimate of a loss of $1.20. This compares to loss of $0.84 per share a year ago.
zacks.com
Read More
Phathom Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update
FLORHAM PARK, N.J., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, today reported financial results for the second quarter of 2024, and provided recent business updates.
globenewswire.com
Read More
Phathom Pharmaceuticals Announces FDA Approval of VOQUEZNA® (vonoprazan) Tablets for the Relief of Heartburn Associated with Non-Erosive GERD in Adults
VOQUEZNA is now approved and available to treat the largest category of Gastroesophageal Reflux Disease (GERD) VOQUEZNA met its primary endpoint in its Phase 3 pivotal trial by demonstrating a significant and rapid reduction of heartburn with daily treatment VOQUEZNA represents the first major innovation in GERD treatment in over 30 years and the only FDA-approved treatment of its kind available in the U.S. A Media Snippet accompanying this announcement is available by clicking on this link. FLORHAM PARK, N.J.
globenewswire.com
Read More
Phathom Pharmaceuticals: Time To Deliver Promise Of Voquezna After Frustrating Delays
Phathom Pharmaceuticals stock has significantly declined since 2021, despite securing FDA approval for Vonoprazan to treat H. pylori infection and GERD. The company faced delays in launching its products due to the presence of a cancer-causing agent in commercial batches, but eventually received full FDA approval. PHAT aims to target a substantial market opportunity with Vonoprazan, potentially leading to a share price rally and challenging a billion-dollar market cap valuation.
seekingalpha.com
Read More
Ride the Gamma Wave: 3 Stocks on the Verge of a Short Squeeze
One of the fastest ways to make money on the stock market is to gamble on short-term contrarian positions against the shorting interest of a stock. Since every company's proportion of shorted stock is publicly available, it's pretty easy to see which companies are expected to lose value.
investorplace.com
Read More
Phathom Pharmaceuticals, Inc. (PHAT) Q1 2024 Earnings Call Transcript
Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT ) Q1 2024 Results Conference Call May 9, 2024 8:30 AM ET Company Participants Eric Sciorilli - Head of Investor Relations Terrie Curran - President & Chief Executive Officer Martin Gilligan - Chief Commercial Officer Molly Henderson - Chief Financial & Business Officer Conference Call Participants Yatin Suneja - Guggenheim Joseph Stringer - Needham & Company Paul Choi - Goldman Sachs Annabel Samimy - Stifel Matthew Caufield - H.C. Wainright Operator Hello, and welcome to Phathom Pharmaceuticals First Quarter 2024 Earnings Results Call.
seekingalpha.com
Read More
The 3 Best Healthcare Stocks to Buy in May 2024
Healthcare is a basic human need that can withstand economic downturns. Indeed, this important endeavor receives a huge amount of funds in developed countries globally and the West in particular.
investorplace.com
Read More
Phathom Pharmaceuticals, Inc. (PHAT) Reports Q1 Loss, Lags Revenue Estimates
Phathom Pharmaceuticals, Inc. (PHAT) came out with a quarterly loss of $1.42 per share versus the Zacks Consensus Estimate of a loss of $1.43. This compares to loss of $0.89 per share a year ago.
zacks.com
Read More
Phathom Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update
FLORHAM PARK, N.J., May 09, 2024 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, today reported financial results for the first quarter of 2024, and provided recent business highlights.
globenewswire.com
Read More
Phathom Pharmaceuticals to Participate in the 23rd Annual Needham Virtual Healthcare Conference
FLORHAM PARK, N.J., April 03, 2024 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, announced today that members of the management team will participate in a fireside chat at the 23rd Annual Needham Virtual Healthcare Conference on Wednesday, April 10, 2024, at 9:30 a.m. ET.
globenewswire.com
Read More
Phathom Pharmaceuticals Launches Direct-to-Consumer Campaign, “VOQUEZNA Can Kick Some Acid”
National TV and digital media campaign aims to motivate millions of people suffering from Erosive GERD to learn more about VOQUEZNA® (vonoprazan), the first and only FDA-approved potassium-competitive acid blocker (PCAB) National TV and digital media campaign aims to motivate millions of people suffering from Erosive GERD to learn more about VOQUEZNA® (vonoprazan), the first and only FDA-approved potassium-competitive acid blocker (PCAB)
globenewswire.com
Read More
Phathom: Undervalued Biotech With Possible GERD Treatment Label Expansion
The FDA has set a target action date of July 19, 2024, for expanded approval of Voquenza, which would target the larger Non-Erosive GERD patient population. The global market for GERD therapies is expected to be $3.4 billion by 2032. A soon-to-be-initiated phase 3 study in 2024 is going to explore the use of Voquenza with "As Needed" dosing to treat Non-Erosive GERD patients.
seekingalpha.com
Read More
Phathom Pharmaceuticals, Inc. (PHAT) Q4 2023 Earnings Call Transcript
Phathom Pharmaceuticals, Inc. (PHAT) Q4 2023 Earnings Call Transcript
seekingalpha.com
Read More
Phathom Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
FLORHAM PARK, N.J., March 07, 2024 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, today reported financial results for the fourth quarter and full year ended December 31, 2023, and provided recent business highlights.
globenewswire.com
Read More
Phathom Pharmaceuticals to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on Thursday, March 7, 2024
Management to host conference call on Thursday, March 7, 2024, at 8:30 a.m. ET FLORHAM PARK, N.J.
globenewswire.com
Read More
Phathom Pharmaceuticals to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
FLORHAM PARK, N.J., Jan. 31, 2024 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, announced today that members of the management team will participate in a fireside chat at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference on Wednesday, February 7, 2024, at 1:30 p.m.
globenewswire.com
Read More
Phathom Pharma Is A Buy Before July PDUFA
Phathom Pharmaceuticals' stock is down 35% from its August highs and is now trading at $9. The company has two approved indications for its drug vonoprazan and an upcoming PDUFA. Phathom has a cash balance of $213mn and a cash runway of 8-9 quarters, making it an attractive investment opportunity.
seekingalpha.com
Read More
Phathom Pharmaceuticals Announces FDA Acceptance for Filing of VOQUEZNA® (vonoprazan) Tablets New Drug Application for the Treatment of Heartburn Associated with Non-Erosive GERD
FLORHAM PARK, N.J., Dec. 06, 2023 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, announced today the FDA has accepted for review the company's NDA for VOQUEZNA (vonoprazan) as a daily treatment of heartburn associated with Non-Erosive gastroesophageal reflux disease (GERD) in adults. The FDA has assigned the application a standard 10-month review with a Prescription Drug User Fee Act (PDUFA) target action date of July 19, 2024.
globenewswire.com
Read More
Phathom Pharmaceuticals Announces Commercial Availability of VOQUEZNA® (vonoprazan) Tablets, a Powerful First-In-Class PCAB for the Treatment of Erosive GERD and Relief of Associated Heartburn
VOQUEZNA, the first and only FDA-approved potassium-competitive acid blocker (PCAB), is now available through major retail pharmacies and BlinkRx, an end-to-end digital fulfillment channel VOQUEZNA tablets in 30-count bottles are now commercially available for the healing and maintenance of healing of all severities of Erosive GERD, and relief of heartburn associated with Erosive GERD 1 FLORHAM PARK, N.J., Nov. 28, 2023 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, today announced the U.S. commercial availability of VOQUEZNA® (vonoprazan).
globenewswire.com
Read More
Phathom Pharmaceuticals Reports Third Quarter 2023 Results and Recent Business Updates
FLORHAM PARK, N.J., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, today reported financial results for the third quarter of 2023 and provided updates on recent regulatory and business progress.
globenewswire.com
Read More
Phathom Pharmaceuticals Announces FDA Approval of VOQUEZNA® (vonoprazan) Tablets for the Treatment of Erosive GERD and Relief of Heartburn Associated with Erosive GERD in Adults
FLORHAM PARK, N.J., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, announced today the U.S. Food and Drug Administration (FDA) has approved VOQUEZNA® (vonoprazan) tablets 10 mg and 20 mg, a novel potassium-competitive acid blocker (PCAB), as a new treatment for adults for the healing of all grades of Erosive Esophagitis, also known as Erosive GERD (gastroesophageal reflux disease), maintenance of healing of all grades of Erosive GERD, and relief of heartburn associated with Erosive GERD.2
globenewswire.com
Read More
Phathom Pharmaceuticals Announces FDA Approval of Reformulated Vonoprazan Tablets for VOQUEZNA® TRIPLE PAK® (vonoprazan, amoxicillin, clarithromycin) and VOQUEZNA® DUAL PAK® (vonoprazan, amoxicillin) for the Treatment of H. pylori Infection in Adults
FLORHAM PARK, N.J., Oct. 30, 2023 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, announced that the U.S. Food and Drug Administration (FDA) has approved the Prior Approval Supplement (PAS) for the reformulation of vonoprazan tablets for both VOQUEZNA TRIPLE PAK (vonoprazan tablets, amoxicillin capsules, clarithromycin tablets) and VOQUEZNA DUAL PAK (vonoprazan tablets, amoxicillin capsules), for the treatment of Helicobacter pylori (H. pylori) infection in adults. VOQUEZNA treatment regimens contain antibiotics conveniently packaged with vonoprazan, a novel potassium-competitive acid blocker (PCAB) and the first innovative acid suppressant from a new drug class approved in the U.S. in over 30 years.
globenewswire.com
Read More
Following Up On Phathom Pharmaceuticals
Phathom Pharmaceuticals is a small biopharma firm focused on developing treatments for gastrointestinal diseases. The company has recently filed some marketing applications around its primary drug candidate. The company ended the second quarter with just under $250 million in cash and marketable securities, and raised over $140 million via a secondary offering in front of launch activities.
seekingalpha.com
Read More
Phathom Pharmaceuticals Announces Vonoprazan NDA Submission for Non-Erosive GERD
FLORHAM PARK, N.J., Sept. 26, 2023 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, today announced the submission of an NDA to the FDA for vonoprazan as a daily treatment for Non-Erosive gastroesophageal reflux disease (GERD) in adults. The regulatory submission is supported by the positive data from the PHALCON-NERD-301 study, a Phase 3 study evaluating the efficacy and safety of vonoprazan for the daily treatment of adults with Non-Erosive GERD (NERD). Vonoprazan is an investigational first-in-class potassium-competitive acid blocker (PCAB) from a novel class of medicines that block acid secretion in the stomach.
globenewswire.com
Read More
Phathom Pharmaceuticals Announces Submission of Six-Month Stability Data in Support of Erosive GERD New Drug Application
FLORHAM PARK, N.J., Aug. 21, 2023 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, today announced it has submitted to the FDA six-month stability data from its long-term and accelerated stability program for its reformulated vonoprazan tablets. The additional stability was required for the FDA to complete its NDA review for vonoprazan, a novel first-in-class potassium-competitive acid blocker (PCAB), for the treatment of Erosive GERD (gastroesophageal reflux disease), also referred to as erosive esophagitis.
globenewswire.com
Read More
Phathom Pharmaceuticals Reports Second Quarter 2023 Results
FLORHAM PARK, N.J., Aug. 10, 2023 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, today reported financial results for the second quarter of 2023 and provided updates on recent regulatory and business progress.
globenewswire.com
Read More
3 Cheap Biotech Stocks That Smart Investors Will Snap Up Now
One of the safest sectors on the market is biotech. After all, we can't stop people from aging — at least not yet.
investorplace.com
Read More
Phathom Pharma: Time To Take Profits (Rating Downgrade)
Phathom Pharmaceuticals, Inc. is trading near 52-week highs. Despite its potential, there are reasons, like a competitive market, why we should take profits on Phathom Pharmaceuticals. If it falls back without major negative reasons before approval, we can always double down.
seekingalpha.com
Read More
3 Top Breakout Stocks Worth a Buy for Attractive Returns
Phathom Pharmaceuticals (PHAT), Universal Stainless & Alloy Products (USAP) and Arlo Technologies (ARLO) are the breakout picks for today.
zacks.com
Read More
Does Phathom Pharmaceuticals, Inc. (PHAT) Have the Potential to Rally 81.38% as Wall Street Analysts Expect?
The mean of analysts' price targets for Phathom Pharmaceuticals, Inc. (PHAT) points to an 81.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
zacks.com
Read More
Phathom Pharmaceuticals, Inc. (PHAT) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
Phathom Pharmaceuticals, Inc. (PHAT) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
zacks.com
Read More
Should You Buy Phathom Pharmaceuticals, Inc. (PHAT) After Golden Cross?
Phathom Pharmaceuticals, Inc. (PHAT) reached a significant support level, and could be a good pick for investors from a technical perspective. Recently, PHAT's 50-day simple moving average broke out above its 200-day moving average; this is known as a "golden cross.
zacks.com
Read More
Phathom (PHAT) Up 8% on Erosive Esophagitis Drug's CRL Update
Phathom Pharmaceuticals (PHAT) announces a regulatory update regarding vonoprazan for the treatment of erosive esophagitis and H. pylori infection.
zacks.com
Read More
Here's Why Phathom Pharmaceuticals, Inc. (PHAT) Is a Great 'Buy the Bottom' Stock Now
Phathom Pharmaceuticals, Inc. (PHAT) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
zacks.com
Read More
All You Need to Know About Phathom Pharmaceuticals, Inc. (PHAT) Rating Upgrade to Buy
Phathom Pharmaceuticals, Inc. (PHAT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
zacks.com
Read More
Phathom's stock falls after receiving FDA letters
Shares of Phathom Pharmaceuticals Inc. PHAT, -0.60% tumbled about 23% in premarket trading on Friday, the day after the company said it received complete response letters from the Food and Drug Administration related to vonoprazan, which is approved for two indications and had also been submitted to the regulator as a potential treatment for erosive esophagitis. Phathom said it plans to meet with the FDA in the first quarter of this year to discuss resubmitting vonoprazan.
marketwatch.com
Read More
Why Shares of Phathom Pharmaceutical Jumped This Week
Investors are reading between the lines to see if the company is fixing its problems regarding its lead therapy.
fool.com
Read More
Phathom (PHAT) Down on Regulatory Update on Vonoprazan NDA
Phathom Pharmaceuticals, Inc. (PHAT) declines as the FDA decides to not take any action on Phathom's new drug application (NDA) for vonoprazan for treating erosive esophagitis.
zacks.com
Read More
Phathom Pharma: Approved Drugs, Upcoming PDUFA, Smallish Addressable Market
PHAT, a Takeda spinoff, has a drug approved in H. pylori. The same drug has a PDUFA in a GERD subtype.
seekingalpha.com
Read More
Phathom Pharmaceuticals to Present at the H.C. Wainwright 24th Annual Global Investment Conference
FLORHAM PARK, N.J., Sept. 07, 2022 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases and disorders, announced today that members of the management team will present virtually at the H.C. Wainwright 24th Annual Global Investment Conference.
globenewswire.com
Read More
Phathom Pharmaceuticals to Present at the 2022 Jefferies Healthcare Conference
FLORHAM PARK, N.J., June 01, 2022 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases and disorders, announced today that members of the management team will participate in a fireside chat at the Jefferies Healthcare Conference on Wednesday, June 8, 2022 at 1:30 p.m. ET.
globenewswire.com
Read More
Phathom Pharmaceuticals to Present Data at DDW 2022 Annual Meeting
FLORHAM PARK, N.J., May 17, 2022 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), an innovative biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, announced today the company will present findings from multiple studies at Digestive Disease Week® (DDW) 2022, being held May 21-24 in person in San Diego, CA and virtually.
globenewswire.com
Read More
Phathom Pharmaceuticals to Present at the 21st Annual Needham Virtual Healthcare Conference
FLORHAM PARK, N.J., April 01, 2022 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, announced today that members of the management team will participate in a fireside chat at the 21st Annual Needham Virtual Healthcare Conference on Tuesday, April 12, 2022 at 9:30 a.m. ET.
globenewswire.com
Read More
Phathom Pharma's Digestive Disease Candidate Meets Primary Goal In Mid-Stage Study
Phathom Pharmaceuticals Inc PHAT reported topline results from the PHALCON-NERD Phase 2 study of vonoprazan as an on-demand therapy to relieve episodic heartburn in non-erosive gastroesophageal reflux disease (NERD). Get the Inside Access Traders Are Using to Profit More and Win Bigger.
benzinga.com
Read More
Phathom Pharmaceuticals: Undiscovered Gem
Phathom Pharmaceuticals: Undiscovered Gem
seekingalpha.com
Read More
Phathom Pharmaceuticals Announces Positive Topline Results from PHALCON-EE Pivotal Phase 3 Erosive Esophagitis Trial
FLORHAM PARK, N.J., Oct. 18, 2021 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, today announced that vonoprazan successfully met its primary endpoints and key secondary superiority endpoints in PHALCON-EE, a pivotal phase 3 trial evaluating vonoprazan versus lansoprazole for the treatment of erosive esophagitis. Based on the positive PHALCON-EE data, Phathom plans to submit an NDA to the U.S. Food and Drug Administration seeking the following indications: healing of all grades of EE and relief of heartburn, and maintenance of healing of all grades of EE and relief of heartburn.
globenewswire.com
Read More
Phathom Pharmaceuticals Announces Results from VONO-103, a Phase 1 Study Evaluating Gastric Acid Inhibition of Vonoprazan and Lansoprazole (PREVACID®)
Vonoprazan 20 mg demonstrated significantly greater acid suppressive effects over the 7-day study period compared to lansoprazole (PREVACID®) 30 mg, a proton pump inhibitor (PPI)
globenewswire.com
Read More
Phathom Pharmaceuticals Secures $200 Million Term Loan Facility from Hercules Capital
FLORHAM PARK, N.J., Sept. 20, 2021 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, today reported it has obtained a $200 million term loan facility from Hercules Capital, Inc. (NYSE: HTGC), a leader in customized debt financing for companies in life sciences and technology-related markets. This additional capital further strengthens Phathom's balance sheet in advance of anticipated key catalysts, including data from the pivotal PHALCON-EE Phase 3 trial of vonoprazan for the treatment of erosive esophagitis in October 2021, data from the Phase 2 trial of vonoprazan for the treatment of non-erosive reflux disease in the first quarter of 2022, and FDA approval and commercial launch of vonoprazan-based regimens for the treatment of H. pylori in the second half of 2022. This non-dilutive financing extends Phathom's projected cash runway to mid-2023 based on the Company's current operating plans.
globenewswire.com
Read More
Phathom Pharmaceuticals to Participate in the Morgan Stanley 19th Annual Global Healthcare Conference
FLORHAM PARK, N.J., Aug. 31, 2021 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, announced today that Terrie Curran, President and CEO, Azmi Nabulsi, M.D., Chief Operating Officer, and Martin Gilligan, Chief Commercial Officer, will participate in a fireside chat at the Morgan Stanley 19th Annual Global Healthcare Conference on Tuesday, September 14, 2021 at 11:00 a.m. ET.
globenewswire.com
Read More
Phathom Pharmaceuticals Mourns the Loss of Chairman and Founder, Tadataka "Tachi" Yamada, M.D.
FLORHAM PARK, N.J., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, announced today the sad news that its chairman and founder, Dr. Tachi Yamada, passed away suddenly at his Seattle, Washington home on August 4.
globenewswire.com
Read More
Phathom Pharmaceuticals to Participate in the BMO Biopharma Spotlight Series: Innovation in GI
FLORHAM PARK, N.J., Aug. 02, 2021 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, announced today that Terrie Curran, Phathom's President and Chief Executive Officer, will participate in the “Innovation in GI” panel discussion at the BMO Biopharma Spotlight Series virtual conference on Thursday, August 12, 2021 at 10:50 a.m. ET.
globenewswire.com
Read More
Phathom Pharmaceuticals to Present at the Jefferies Virtual Healthcare Conference
FLORHAM PARK, N.J., May 25, 2021 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, announced today that members of the management team will participate in a fireside chat at the Jefferies Virtual Healthcare Conference on Tuesday, June 1, 2021 at 10:00 a.m. ET.
globenewswire.com
Read More
Phathom Pharmaceuticals Reports First Quarter 2021 Results and Provides Recent Business Updates
FLORHAM PARK, N.J., May 11, 2021 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, today reported financial results for the first quarter of 2021 and provided an update on its recent clinical and organizational progress.
globenewswire.com
Read More
Phathom Pharmaceuticals to Present at the Bank of America Securities 2021 Virtual Healthcare Conference
FLORHAM PARK, N.J., May 06, 2021 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, announced today that members of the management team will participate in a fireside chat at the Bank of America Securities 2021 Virtual Healthcare Conference on Thursday, May 13, 2021 at 8:45 a.m. ET.
globenewswire.com
Read More
Phantom Pharmaceuticals Could See Substantial Upside With 2 Upcoming Phase 3 Readouts
Phantom Pharmaceuticals Could See Substantial Upside With 2 Upcoming Phase 3 Readouts
seekingalpha.com
Read More
Why Mustang Bio, Phathom Pharma And More Are Moving Today
Mustang Bio (NASDAQ: MBIO) shares are trading higher after the company announced the FDA has lifted the clinical hold for its pivotal phase 2 MB-107 clinical trial. The company plans to enroll the first patient in the second quarter of 2021.
benzinga.com
Read More
Phathom Pharmaceuticals Announces Completion of Patient Enrollment in Pivotal Phase 3 Helicobacter pylori (H. pylori) Trial
FLORHAM PARK, N.J., Jan. 19, 2021 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, today announced that it has completed patient enrollment in PHALCON-HP, a pivotal Phase 3 clinical trial of vonoprazan in combination with amoxicillin (vonoprazan dual therapy) and vonoprazan in combination with amoxicillin and clarithromycin (vonoprazan triple therapy) for the eradication of H. pylori infection. Phathom continues to expect topline results from the study in the second quarter of 2021.
globenewswire.com
Read More
Frazier Healthcare Partners Announces Multiple Promotions on its Life Sciences Team
MENLO PARK, Calif.--(BUSINESS WIRE)--Frazier Healthcare Partners announced the promotion of several members on its Life Sciences team: Aditya Kohli to Venture Partner, Anna Chen to Vice President, and Max Nowicki to Senior Associate. Aditya Kohli, Ph.D., joined the Frazier Life Sciences team in 2016 and focuses on company creation. He co-founded Phathom Pharmaceuticals (NASDAQ: PHAT) and Scout Bio, and helped launch Passage Bio (NASDAQ: PASG). Dr. Kohli serves as the Chief Business Officer of P
businesswire.com
Read More
Phathom Pharmaceuticals Announces Pricing of Public Offering of Common Stock
FLORHAM PARK, N.J., Dec. 16, 2020 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, announced today the pricing of its underwritten public offering of 2,250,000 shares of its common stock at a price to the public of $42.00 per share. All of the shares to be sold in the offering are being sold by Phathom. The gross proceeds to Phathom from the offering, before deducting the underwriting discounts and commissions and other offering expenses, are expected to be $94.5 million. In addition, Phathom has granted the underwriters a 30-day option to purchase up to an additional 337,500 shares of common stock at the public offering price, less underwriting discounts and commissions. The offering is expected to close on or about December 21, 2020.
globenewswire.com
Read More
Phathom Pharmaceuticals Announces Proposed Public Offering of 2,250,000 Shares of Common Stock
FLORHAM PARK, N.J., Dec. 15, 2020 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, announced today that it intends to offer and sell, subject to market and other conditions, 2,250,000 shares of its common stock in an underwritten public offering. In addition, Phathom intends to grant the underwriters a 30-day option to purchase up to an additional 337,500 shares of common stock. All of the shares to be sold in the offering are to be sold by Phathom. There can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
globenewswire.com
Read More
Phathom Pharmaceuticals Announces Plans to Initiate Vonoprazan Development Program in Non-Erosive Reflux Disease (NERD)
Management and Key Opinion Leaders to discuss NERD and the vonoprazan NERD development program during virtual Investor Day webcast today at 1:00 PM (ET) Management and Key Opinion Leaders to discuss NERD and the vonoprazan NERD development program during virtual Investor Day webcast today at 1:00 PM (ET)
globenewswire.com
Read More
Phathom Pharmaceuticals Announces Completion of Patient Enrollment in Pivotal Phase 3 Erosive Esophagitis Trial
Topline results expected in second half of 2021 Topline results expected in second half of 2021
globenewswire.com
Read More
Phathom Pharmaceuticals to Participate at Upcoming Investor Healthcare Conferences
FLORHAM PARK, N.J., Nov. 27, 2020 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, announced today that members of the management team will participate at two upcoming virtual investor conferences in December, including:
globenewswire.com
Read More
Phathom Pharmaceuticals to Host Virtual Investor Day
FLORHAM PARK, N.J., Nov. 19, 2020 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, today confirmed it will host a virtual Investor Day on December 14, 2020 from 1 pm to 3:30 pm Eastern Time. Members of Phathom's management team and gastroenterology key opinion leaders will provide updates on the company's pipeline and commercial strategy.
globenewswire.com
Read More
Phathom Pharmaceuticals to Present at the Jefferies Virtual London Healthcare Conference
FLORHAM PARK, N.J., Nov. 13, 2020 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, announced today that members of the management team will participate in a fireside chat at the Jefferies Virtual London Healthcare Conference on Wednesday, November 18, 2020 at 3:15 p.m. GMT (10:15 a.m. ET).
globenewswire.com
Read More